Avanos Medical (NYSE:AVNS) Downgraded by Wall Street Zen to Hold

Avanos Medical (NYSE:AVNS) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other research analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Avanos Medical has a consensus rating of “Reduce”.

Avanos Medical Price Performance

NYSE:AVNS opened at $13.71 on Friday. The firm has a market capitalization of $637.33 million, a price-to-earnings ratio of -8.67 and a beta of 1.07. Avanos Medical has a 52-week low of $9.30 and a 52-week high of $15.68. The stock has a fifty day moving average of $13.49 and a 200 day moving average of $12.26. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.26 and a current ratio of 2.15.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.05. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business had revenue of $180.90 million for the quarter, compared to analyst estimates of $174.70 million. During the same period in the prior year, the company earned $0.43 EPS. The company’s quarterly revenue was up .7% compared to the same quarter last year. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, research analysts expect that Avanos Medical will post 1.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Avanos Medical

Institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its position in Avanos Medical by 132.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,496 shares of the company’s stock worth $28,000 after buying an additional 1,423 shares during the last quarter. Russell Investments Group Ltd. grew its position in Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after acquiring an additional 2,307 shares during the last quarter. Versant Capital Management Inc raised its stake in shares of Avanos Medical by 49.7% during the third quarter. Versant Capital Management Inc now owns 2,692 shares of the company’s stock worth $31,000 after acquiring an additional 894 shares in the last quarter. Wexford Capital LP purchased a new position in shares of Avanos Medical during the third quarter worth approximately $70,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.